insitro to Acquire CombinAbleAI to Complete its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design

SOUTH SAN FRANCISCO, Calif., January 12, 2026--insitro, the AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insitro’s TherML™ ...
WWLP-22News

InnoPharm-2025 to Spotlight Breakthroughs in Drug Discovery, Delivery & Novel Modalities

Global pharma leaders, scientists, and innovators will gather in San Francisco from Nov 03–05, 2025, to explore transformative sessions. InnoPharm-2025 is a global stage where science meets innovation ...
News Medical

Investigate renal drug transport modalities in vitro with the aProximate™ PTC model

aProximate TM PTCs maintain high expression of key transporters involved in drug handling, including megalin and cubilin, making them ideal for studying drug transporters and drug interactions with ...
Nature

Dual-Modality Accurate Visualization of Drug Synergy Based on Mass Spectrometry and Fluorescence Imaging

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...